Clinical Trial Update: Phase I Study of OriC902 in Treatment of Advanced HCC [Phase 1]

View source ↗

Summary

Phase I trial of OriC902 for advanced hepatocellular carcinoma is currently recruiting, sponsored by Peking University.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• OriC902

Snippet

Sponsor: Peking University | Conditions: HCC | Phase 1 | Status: RECRUITING